争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 1 条
2019
第一三共对 Seattle Genetics 提起确认之诉
提起诉讼
第一三共因抗体药物偶联物（包括 DS-8201）所使用的连接子技术权利争议，在特拉华州联邦地区法院提起确认之诉。Seattle Genetics 表示，第一三共的起诉绕过了双方原协议中的争议解决程序；双方均对对方关于该技术权利的主张提出异议。
来源摘录
“By filing this lawsuit, Daiichi Sankyo has circumvented the process underway between the parties pursuant to these provisions,” Seattle Genetics wrote in a statement responding to the legal action.
Daiichi revealed it has filed a declaratory judgement action in the District Court of Delaware.
The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201.